Timpani Capital Management LLC decreased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,708 shares of the specialty pharmaceutical company’s stock after selling 278 shares during the quarter. Supernus Pharmaceuticals makes up about 1.6% of Timpani Capital Management LLC’s investment portfolio, making the stock its 19th largest position. Timpani Capital Management LLC owned 0.20% of Supernus Pharmaceuticals worth $4,341,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Louisiana State Employees Retirement System boosted its stake in Supernus Pharmaceuticals by 0.5% in the 2nd quarter. Louisiana State Employees Retirement System now owns 20,500 shares of the specialty pharmaceutical company’s stock valued at $884,000 after buying an additional 100 shares in the last quarter. Arizona State Retirement System boosted its stake in Supernus Pharmaceuticals by 0.4% in the 2nd quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after buying an additional 100 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Supernus Pharmaceuticals by 3.2% in the 1st quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 170 shares in the last quarter. Texas Permanent School Fund boosted its stake in Supernus Pharmaceuticals by 0.5% in the 1st quarter. Texas Permanent School Fund now owns 36,288 shares of the specialty pharmaceutical company’s stock valued at $1,136,000 after buying an additional 178 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Supernus Pharmaceuticals by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 93,907 shares of the specialty pharmaceutical company’s stock valued at $4,047,000 after buying an additional 288 shares in the last quarter. 95.38% of the stock is currently owned by institutional investors and hedge funds.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 3,735 shares of the firm’s stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $44.90, for a total value of $167,701.50. Following the sale, the vice president now owns 21,209 shares of the company’s stock, valued at approximately $952,284.10. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 2,556 shares of the firm’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $44.90, for a total value of $114,764.40. Following the completion of the sale, the vice president now directly owns 24,944 shares in the company, valued at approximately $1,119,985.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,000 shares of company stock worth $450,224. Company insiders own 6.70% of the company’s stock.

SUPN has been the topic of several recent analyst reports. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a research note on Thursday, July 13th. Cantor Fitzgerald boosted their price target on Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a research note on Wednesday, July 5th. Jefferies Group LLC boosted their price target on Supernus Pharmaceuticals from $45.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, June 28th. BidaskClub lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $47.00 price target (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $48.29.

COPYRIGHT VIOLATION NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) Position Reduced by Timpani Capital Management LLC” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/09/supernus-pharmaceuticals-inc-supn-position-reduced-by-timpani-capital-management-llc.html.

Supernus Pharmaceuticals, Inc. (SUPN) traded up 1.67% during trading on Friday, reaching $48.60. The company’s stock had a trading volume of 806,019 shares. Supernus Pharmaceuticals, Inc. has a 1-year low of $17.25 and a 1-year high of $49.95. The company’s 50 day moving average price is $43.51 and its 200-day moving average price is $36.73. The stock has a market cap of $2.46 billion, a P/E ratio of 24.52 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. The firm had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. Equities analysts forecast that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.